Welcome to Medications.com

Boehringer Ingelheim Announces Enrollment is Complete for the ... - Earthtimes

The RE-LY trial is comparing two blinded doses of oral dabigatran etexilate with warfarin sodium (target INR 2.0-3.0) in patients with non-valvular atrial ...

http://www.earthtimes.org/article... | Posted: Thu Jan 17 10:13:13 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea